Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil

European Journal of Cancer Part A

Volumn 33, Issue SUPPL. 1, 1997, Pages

  Burris, H ^a   Storniolo, A M ^b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Chemotherapy; Clinical benefit; Clinical trial; Gemcitabine; Pancreas cancer; Quality of life; Review

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

EID: 0030964122     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00324-3     Document Type: Conference Paper

References (8)

1. Lionetto R, Pugliese V, Bruzzi P, Rosso R. No standard treatment is available for pancreas cancer. Eur J Cancer 1995, 31, 882-887.
2. Brennan MF, Kinsella TJ, Casper ES. Cancer of the pancreas, de Vita V, Hellman S, Rosenberg SA In Cancer Principles and Practice of Oncology, eds. Philadelphia, JB Lippincott Co, 1993, 849-882.
3. Van Cutsem E, Fevery J. Pancreatic cancer: a plea for more trials. Eur J Cancer 1995, 31, 867-869.
4. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994, 12, 29-34.
5. Moore M, Andersen J, Burris H, et al. A randomized trial of gemcitabine (GEM) versus 5FU as first-line therapy in advanced pancreatic cancer. Proc Am Soc Clin Oncol 1995, 14, 199, abstract No. 473.
6. Rothenberg ML, Moore MJ, Cripps CM, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol (in press).
7. Fishman B, Pasternak S, Wallenstein SL, et al. The memorial pain assessment card: a valid instrument for the evaluation of cancer pain. Cancer 1987, 60, 1151-1158.
8. Chick J. A system for assessing Clinical Benefit for patients with non-small cell lung cancer (NSCLC). ICACT 1996, abstract 561.